Catalyst Biosciences (FRA:HGF2) Debt-to-Equity : 0.00 (As of Sep. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Catalyst Biosciences Debt-to-Equity?

Catalyst Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was €0.00 Mil. Catalyst Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was €0.00 Mil. Catalyst Biosciences's Total Stockholders Equity for the quarter that ended in Sep. 2023 was €3.30 Mil. Catalyst Biosciences's debt to equity for the quarter that ended in Sep. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Catalyst Biosciences's Debt-to-Equity or its related term are showing as below:

FRA:HGF2' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.03 Max: 1.51
Current: 0.01

During the past 13 years, the highest Debt-to-Equity Ratio of Catalyst Biosciences was 1.51. The lowest was 0.00. And the median was 0.03.

FRA:HGF2's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs FRA:HGF2: 0.01

Catalyst Biosciences Debt-to-Equity Historical Data

The historical data trend for Catalyst Biosciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalyst Biosciences Debt-to-Equity Chart

Catalyst Biosciences Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

0.03

0.02

0.06

Catalyst Biosciences Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial															0.01	-	-	-	-

Competitive Comparison of Catalyst Biosciences's Debt-to-Equity

For the Biotechnology subindustry, Catalyst Biosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Catalyst Biosciences's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Catalyst Biosciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Catalyst Biosciences's Debt-to-Equity falls into.

Catalyst Biosciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Catalyst Biosciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.036	+	0)	/	-20.474
	=	-0.00

Catalyst Biosciences's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	3.295
	=	0.00

Catalyst Biosciences (FRA:HGF2) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Catalyst Biosciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Catalyst Biosciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Catalyst Biosciences (FRA:HGF2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Catalyst Biosciences Inc (FRA:HGF2) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

611 Gateway Boulevard, Suite 710, South San Francisco, CA, USA, 94080

Website

https://www.catalystbiosciences.com

Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. It mainly focuses on developing novel medicines to address serious medical conditions for individuals in need of treatment options. The company emphasizes product development efforts in the field of hemostasis and to develop valuable therapies for individuals with hemophilia. It is engaged in the clinical development of improved, next-generation subcutaneous prophylaxis using enhanced potency Factor VIIa and Factor IX variants.

Catalyst Biosciences (FRA:HGF2) Headlines

No Headlines